Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonectomy | 7 | 2026 | 131 | 3.680 |
Why?
|
| Lung Neoplasms | 16 | 2026 | 712 | 3.520 |
Why?
|
| Esophagectomy | 5 | 2026 | 53 | 3.010 |
Why?
|
| Robotic Surgical Procedures | 5 | 2026 | 172 | 2.930 |
Why?
|
| Esophageal Neoplasms | 4 | 2026 | 94 | 2.840 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2026 | 186 | 2.640 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2014 | 378 | 1.770 |
Why?
|
| Frailty | 3 | 2026 | 132 | 1.600 |
Why?
|
| Postoperative Complications | 6 | 2026 | 1336 | 1.450 |
Why?
|
| Databases, Factual | 5 | 2026 | 888 | 1.070 |
Why?
|
| Neoplasm Staging | 11 | 2026 | 553 | 0.980 |
Why?
|
| Neoadjuvant Therapy | 2 | 2026 | 102 | 0.980 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2025 | 42 | 0.960 |
Why?
|
| Conversion to Open Surgery | 1 | 2025 | 15 | 0.900 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2025 | 62 | 0.870 |
Why?
|
| Resuscitation | 1 | 2025 | 67 | 0.860 |
Why?
|
| Thoracic Surgery | 2 | 2025 | 80 | 0.860 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2025 | 128 | 0.830 |
Why?
|
| Retrospective Studies | 18 | 2026 | 6953 | 0.830 |
Why?
|
| Carcinoid Tumor | 2 | 2014 | 12 | 0.820 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 36 | 0.810 |
Why?
|
| Quality Improvement | 3 | 2026 | 473 | 0.780 |
Why?
|
| Aged | 20 | 2026 | 15141 | 0.770 |
Why?
|
| General Surgery | 1 | 2025 | 210 | 0.750 |
Why?
|
| Societies, Medical | 1 | 2025 | 401 | 0.750 |
Why?
|
| Education, Medical, Graduate | 1 | 2025 | 348 | 0.730 |
Why?
|
| Robotics | 1 | 2022 | 86 | 0.660 |
Why?
|
| Male | 24 | 2026 | 31398 | 0.630 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 533 | 0.620 |
Why?
|
| Middle Aged | 16 | 2026 | 18491 | 0.620 |
Why?
|
| Adenocarcinoma | 4 | 2026 | 367 | 0.610 |
Why?
|
| Female | 22 | 2026 | 34414 | 0.570 |
Why?
|
| Internship and Residency | 1 | 2025 | 802 | 0.530 |
Why?
|
| Opioid-Related Disorders | 1 | 2025 | 532 | 0.530 |
Why?
|
| Humans | 30 | 2026 | 65826 | 0.520 |
Why?
|
| Risk Assessment | 6 | 2026 | 2113 | 0.520 |
Why?
|
| Neoplasms, Second Primary | 2 | 2014 | 50 | 0.470 |
Why?
|
| United States | 7 | 2026 | 8190 | 0.420 |
Why?
|
| Emergencies | 2 | 2025 | 124 | 0.390 |
Why?
|
| Treatment Outcome | 5 | 2026 | 5830 | 0.390 |
Why?
|
| Risk Factors | 6 | 2026 | 5471 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2026 | 420 | 0.370 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 264 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 1665 | 0.360 |
Why?
|
| Clinical Competence | 2 | 2025 | 731 | 0.290 |
Why?
|
| Length of Stay | 2 | 2026 | 828 | 0.250 |
Why?
|
| New York | 3 | 2014 | 144 | 0.230 |
Why?
|
| Survival Rate | 4 | 2014 | 847 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2025 | 113 | 0.220 |
Why?
|
| Colectomy | 1 | 2026 | 123 | 0.220 |
Why?
|
| Adult | 8 | 2025 | 17567 | 0.220 |
Why?
|
| Time-to-Treatment | 1 | 2026 | 133 | 0.210 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 327 | 0.210 |
Why?
|
| Propensity Score | 1 | 2025 | 192 | 0.210 |
Why?
|
| Rectal Neoplasms | 1 | 2026 | 139 | 0.210 |
Why?
|
| Incidence | 4 | 2021 | 1432 | 0.210 |
Why?
|
| Colonic Neoplasms | 1 | 2026 | 220 | 0.210 |
Why?
|
| Time Factors | 5 | 2014 | 3778 | 0.200 |
Why?
|
| Reoperation | 1 | 2025 | 307 | 0.200 |
Why?
|
| Quality Assurance, Health Care | 1 | 2026 | 253 | 0.200 |
Why?
|
| Stomach | 1 | 2024 | 87 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2026 | 5681 | 0.200 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2023 | 10 | 0.200 |
Why?
|
| Esophageal Diseases | 1 | 2023 | 16 | 0.200 |
Why?
|
| Colorectal Neoplasms | 1 | 2026 | 290 | 0.190 |
Why?
|
| Comorbidity | 1 | 2026 | 1122 | 0.190 |
Why?
|
| Quality Indicators, Health Care | 1 | 2026 | 349 | 0.190 |
Why?
|
| Morbidity | 1 | 2022 | 110 | 0.180 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 124 | 0.180 |
Why?
|
| Elective Surgical Procedures | 1 | 2022 | 120 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 2496 | 0.170 |
Why?
|
| Curriculum | 1 | 2025 | 609 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 413 | 0.160 |
Why?
|
| Logistic Models | 1 | 2024 | 1274 | 0.160 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 145 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2022 | 337 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2737 | 0.140 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2790 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 809 | 0.120 |
Why?
|
| New York City | 2 | 2012 | 96 | 0.120 |
Why?
|
| Prognosis | 3 | 2014 | 1792 | 0.110 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 14 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 375 | 0.100 |
Why?
|
| Mediastinal Neoplasms | 1 | 2013 | 21 | 0.100 |
Why?
|
| False Positive Reactions | 1 | 2012 | 77 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2013 | 237 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 210 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 233 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 312 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1117 | 0.080 |
Why?
|
| Smoking | 1 | 2014 | 864 | 0.070 |
Why?
|
| Disease Progression | 1 | 2013 | 1229 | 0.070 |
Why?
|
| Young Adult | 2 | 2013 | 4878 | 0.060 |
Why?
|
| Operative Time | 1 | 2026 | 94 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 932 | 0.060 |
Why?
|
| Operating Rooms | 1 | 2026 | 60 | 0.060 |
Why?
|
| Radius | 1 | 2023 | 20 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 94 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 148 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2022 | 11 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 12 | 0.050 |
Why?
|
| Cause of Death | 2 | 2014 | 221 | 0.050 |
Why?
|
| Endosonography | 1 | 2022 | 27 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2022 | 46 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 289 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 31 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2026 | 439 | 0.040 |
Why?
|
| Brazil | 1 | 2021 | 104 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2026 | 492 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 67 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 199 | 0.040 |
Why?
|
| Walking | 1 | 2020 | 248 | 0.030 |
Why?
|
| Medicare | 1 | 2021 | 629 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 969 | 0.030 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 2 | 0.030 |
Why?
|
| Mediastinoscopy | 1 | 2013 | 8 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 102 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 129 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 196 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 92 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 17 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 74 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 245 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 237 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 463 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 579 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 746 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 466 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 881 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2649 | 0.010 |
Why?
|